The investigators assess whether guanfacine extended release (GXR; 3mg/d) compared with placebo (PBO) will attenuate drinking and drinking-related factors in N=200 men and women with Alcohol Use Disorder (AUD) across 12-weeks.
Phase:
PHASE2
Details
Lead Sponsor:
Indiana University
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)